FY2029 Earnings Estimate for TVTX Issued By HC Wainwright

Travere Therapeutics, Inc. (NASDAQ:TVTX) – HC Wainwright issued their FY2029 earnings per share estimates for shares of Travere Therapeutics in a report issued on Wednesday, January 15th. HC Wainwright analyst E. Arce anticipates that the company will post earnings per share of $4.22 for the year. HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.92) per share.

Several other research firms have also commented on TVTX. Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $9.00 to $27.00 in a report on Monday, October 21st. Piper Sandler lifted their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Wedbush boosted their price target on shares of Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Canaccord Genuity Group reduced their price target on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, September 30th. Finally, Guggenheim lifted their target price on Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Travere Therapeutics Price Performance

NASDAQ TVTX opened at $18.37 on Thursday. The stock’s fifty day moving average price is $18.21 and its 200 day moving average price is $14.47. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -4.04 and a beta of 0.70. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $20.33.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. During the same period in the prior year, the firm posted ($1.17) earnings per share. The company’s quarterly revenue was up 69.6% on a year-over-year basis.

Institutional Trading of Travere Therapeutics

Institutional investors have recently made changes to their positions in the stock. Millennium Management LLC grew its stake in shares of Travere Therapeutics by 33.9% in the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after purchasing an additional 747,406 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in Travere Therapeutics by 203.0% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 615,000 shares of the company’s stock valued at $5,055,000 after purchasing an additional 412,000 shares in the last quarter. Emerald Advisers LLC increased its stake in shares of Travere Therapeutics by 19.8% in the third quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after acquiring an additional 323,513 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in shares of Travere Therapeutics by 26.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock worth $16,588,000 after purchasing an additional 244,444 shares in the last quarter. Finally, Walleye Capital LLC grew its position in Travere Therapeutics by 70.1% in the third quarter. Walleye Capital LLC now owns 488,453 shares of the company’s stock worth $6,833,000 after acquiring an additional 201,282 shares in the last quarter.

Insider Activity

In other Travere Therapeutics news, CAO Sandra Calvin sold 12,090 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $18.30, for a total value of $221,247.00. Following the transaction, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at $1,005,164.10. This trade represents a 18.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jula Inrig sold 2,066 shares of the firm’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total value of $39,460.60. Following the completion of the sale, the insider now owns 59,883 shares in the company, valued at $1,143,765.30. The trade was a 3.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,596 shares of company stock worth $527,262 over the last ninety days. Corporate insiders own 3.75% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.